Shihua Luo

Shihua Luo

Auto-generated profile, based on publicly available information

Shihua Luo

Center for Medical Laboratory Science, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, Guangxi, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2024 in Gene
Verified
Journal Article
Closed access
FCFu Chai
Fu Chai
XCXu Chang
Xu Chang
YLYingliang Lin
Yingliang Lin
XPXiaoxia Pang
Xiaoxia Pang
SLShihua Luo
Shihua Luo
CWChunfang Wang
Chunfang Wang

28 July 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
SLShihua Luo
Shihua Luo
ZDZhiqing Deng
Zhiqing Deng
XZXiaochun Zhang
Xiaochun Zhang
ZPZhenyu Pan
Zhenyu Pan
HXHaibo Xu
Haibo Xu
Background and Aim: Patients with 2019 novel coronavirus disease (COVID‐19) could present with gastrointestinal symptoms without fever or respiratory manifestations, which could be overlooked by health‐care providers. We aimed to evaluate the clinical characteristics of COVID‐19 in patients presenting with initial gastrointestinal symptoms.Methods: We evaluated all confirmed cases of COVID‐19 in Zhongnan Hospital of Wuhan University between January 10 and February 29, 2020. We divided these patients into two groups: patients with initial gastrointestinal symptoms (group A, n = 183) and patients with respiratory syndrome and/or fever (group B, n = 1228). The clinical characteristics, radiological features, and laboratory data were assessed.Results: The clinical procedures of both groups underwent 1–2 weeks rising period and were downward trend at 3 weeks; less than 5% of patients progressed to critical illness. In both groups, mean leukocyte count (P = 0.354) and lymphocyte count (P = 0.386) were below normal, and C‐reactive protein level was elevated (P = 0.412). There was mild liver function injury (aspartate aminotransferase, 65.8 ± 12.7 vs 67.4 ± 9.3 U/L, P = 0.246; alanine aminotransferase, 66.4 ± 13.2 vs 69.6 ± 12.7 U/L, P = 0.352), and normal renal function was intact (blood urea nitrogen 6.4 ± 2.5 vs 5.6 ± 2.8 mmol/L P = 0.358; creatinine 85.7 ± 37.2, 91.2 ± 32.6 μmol/L, P = 0.297). After a series of treatment, 176 and 1169 were stable and alive in groups A and B, respectively. The survival rate did not differ significantly between the groups (P = 0.313).Conclusion: COVID‐19 patients presented with initial gastrointestinal symptoms had similar clinical characteristics and outcomes, when compared with patients with fever and respiratory symptoms.

13 June 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SLShihua Luo
Shihua Luo
JCJianguo Chu
Jianguo Chu
HHHe Huang
He Huang
KYKechun Yao
Kechun Yao
We retrospectively identified 89 consecutive patients from January 2004 to January 2012 to investigate efficacy of direct intrahepatic portocaval shunt (DIPS) combined with inferior vena cava (IVC) stenting for sinusoidal obstruction syndrome (SOS) associated with hepatotoxicity of pyrrolizidine alkaloids. Indications for treatment were variceal hemorrhage and/or refractory ascites. Patients were treated with DIPS plus IVC stenting (group A, n=68) or DIPS alone (group B, n=21). A technical success rate of 100% was obtained in all 89 patients, and there were no early procedure-related adverse events or 30-day mortality. Mean portosystemic gradient decreased in both groups. Changes in aspartate and alanine aminotransferases and total bilirubin did not differ between the groups. Ascites disappeared in group A but was not obvious in group B until IVC stenting. During follow-up, recurrent bleeding and ascites and incidence of hepatic encephalopathy did not differ between the groups. The 1-, 3-, and 5-year survival rate was 98, 89.59, and 80%, respectively. Satisfactory clinical results were obtained for combined DIPS and IVC stenting for SOS associated with pyrrolizidine-alkaloid-related decompensated cirrhosis.

23 August 2017 in EURASIA Journal of Mathematics, Science and Technology Education
Verified
Journal Article
Open access
ZZZu-Chang Zhong
Zu-Chang Zhong
SLShi-Hua Luo
Shi-Hua Luo
WWWencheng Wang
Wencheng Wang
XCXue-Ying Chen
Xue-Ying Chen
YWYi-Lin Wei
Yi-Lin Wei
WMWei-Rong Mo
Wei-Rong Mo
The investment of education capital and fixed assets play an important role in the economic growth of one country, while traditional regression analysis may underestimate or overestimate the contribution of the investment of education capital and fixed assets on economic growth. In this paper,...

1 January 2018 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
CLChao Liu
Chao Liu
GCGuang Chen
Guang Chen
DLDan Liu
Dan Liu
SNShao-Ping Nie
Shao-Ping Nie
XWXiao Wang
Xiao Wang
JWJie Wang
Jie Wang
Background. Coronary artery stenosis is the major pathological change of coronary heart disease (CHD). Within the framework of traditional Chinese medicine (TCM) theory, some kinds of TCM Zheng could exist in patients with CHD; accordingly, TCM practitioners could provide appropriate TCM therapy. However, little is known about the association between TCM Zheng and types of coronary artery stenosis. Such knowledge could help improve the accuracy and effectiveness of efforts to combine CHD treatment with TCM therapy. Therefore, the aim of this study is to determine the association between TCM Zheng and types of coronary artery stenosis. Methods and Design. This is a multicenter, large sample, case series study in 4 tertiary A hospitals from 3 provinces in China. A total of 3,000 eligible patients diagnosed with atherosclerosis or CHD and selected to undergo coronary angiography (CAG) will be enrolled in this study. We will use electronic case report forms (eCRF) to collect information, including baseline characteristics, TCM symptoms, CAG results, and GRACE scores according to standard operating procedures (SOP). Data will be analyzed by SPSS 20.0. Ethics. This study is approved by the Ethics Committee of Guang’anmen Hospital of the China Academy of Chinese Medical Sciences (no. 2017‐058‐KY‐01) and is registered with chictr.org (registration number ChiCTR-ROC-17013221).